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Abstract: Major depressive disorder (MDD) is the leading cause of memory impairment in general population. The 
serotonin hypothesis provides a target model for the treatment of depression and depression-associated memory loss. 5-
HT-1B receptor is suggested as a potential candidate in the pathophysiology of depressive illness. Dysfunction of 5-HT-
1B receptors has been observed previously in depressive patients. Zolmitriptan, 5-HT-1B agonist is clinically 
recommended for the treatment of migraine. However, in present study this drug was tested as a potential treatment for 
depression and associated memory loss by altering the serotonergic function at receptor level. Rats (n=24) were equally 
divided into unstressed and stressed groups. Depression was induced by 19 days of restraint stress for 4 h which was 
followed by forced swim test and pattern separation test to assess depressive symptoms and memory impairment, 
respectively. The initial sign of depression-associated memory loss involves impaired pattern separation which is 
regarded as pseudodementia. In this study stressed rats showed depression- and pseudodementia-like symptoms. After 
the induction of depression, rats were treated with zolmitriptan at a dose of 0.3 mg/kg which resulted in a significant 
attenuation of depression and depression-associated memory impairment. Results are discussed with reference to the 
modulation of function of 5-HT-1B receptor following the administration of exogenous agonist. 
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INTRODUCTION 
 
Major depressive disorder (MDD) is the life threatening 
disease. The estimated risk factor for the occurrence of 
MDD in female is about 20-25% and in males it is about 
7-12% (Svenningsson et al., 2013). The complete 
pathophysiology of depression is still not identified, 
however, serotonergic abnormalities have been frequently 
implicated (Svenningsson et al., 2006). In depressive 
patient abnormal functioning of 5-HT receptors, including 
5-HT-1B, has been reported previously. The 5-HT-1B 
receptors are involved in various physiological responses 
including satiety, temperature regulation and memory 
formation (Tiger et al., 2018). Beside these, the possible 
role of 5-HT-1B in psychiatric illnesses has also been 
suggested. Reduced expression of 5-HT-1B receptors has 
been reported previously in animal model of depression, 
moreover, diminished p11 intracellular signaling 
associated with 5-HT-IB has been observed in 
postmortem brains of depressed persons (Murrough et al., 
2011). The p11 intracellular protein is involved in 
physiological function of 5-HT-1B receptors (Eriksson et 
al., 2013). Anxiolytic effects are the characteristic 
outcome of 5-HT-1B receptors, however, antidepressant 
effects of 5-H-1B agonist are also reported (Tatarczyńska 
et al., 2004). Preclinical study on rodent model of 
depressive symptoms showed the increased efficacy of 
antidepressant drugs when administered along with the 
treatment of 5-HT-1B agonists (Ruf and Bhagwagar et al., 
2009). Clinical studies conducted on MDD patients also 
showed the contribution of 5-HT-1B receptors in 
depression and responsiveness of these receptors when 
the patients were treated with antidepressant drugs (Tiger 
et al., 2018). Zolmitriptan is 5-HT-1B agonist which is 
recommended for the treatment of migraines. The anti-
migraine effects of zolmitriptan are due to 
vasoconstriction. It inhibits increased cerebral blood flow 
triggered by trigeminal nerves. After crossing the blood 
brain barrier, it obstructs trigeminovascular activation in 
the brainstem (Martin et al., 1997).  The 5-HT-1B 
receptors are mainly present on presynaptic sites, 
however, they also regulate the release of other 
neurotransmitters and function as heteroreceptors. 
Antidepressant-like effects of activation of 5-HT-1B 
heteroreceptors in a rodent serotonin-depletion model has 
been observed previously (Nautiyal and  Hen et al., 
2017). 5-HT heteroreceptors give response to the relevant 
5-HT receptor ligand which may result in increased 
release of specific neurotransmitter. This can explain its 
hypothesized deficit in distinct brain areas (Fink and *Corresponding author: e-mail: saida-h1@hotmail.com 
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Göthert et al., 2007). The implication of these receptors in 
memory formation has also been reported. Improved 
memory function has been reported in mice following the 
stimulation of 5-HT-1B receptors by the administration of 
agonist (Eriksson et al., 2013). Depression and memory 
disturbances are co-associated. The memory loss 
secondary to depressive illness is particularly called as 
pseudodementia (Kang et al., 2014). Pseudodementia is 
considered as the precursor of true dementia and if it 
remains untreated then there are chances that it may lead 
severe memory loss in later stages. It has been suggested 
that if the underlying psychiatric illness is treated then 
pseudodementia can be reversed (Kennedy, 2015). 5-HT-
1B receptors are implicated in psychiatric illness and 
antidepressant effects of 5-HT-1B agonists are also 
reported previously. Hence, the current experiment was 
designed to study the function of 5-HT-1B receptors in 
depression. Furthermore, the study also aimed to 
determine the role of 5-HT-1B receptors in memory 
impairment associated with depression in rats. 
 
MATERIALS AND METHODS 
 
Animals 
Twenty four locally bred male albino Wister rats weighing 
150-180 grams purchased from Animal Facility of 
International Center for Chemical and Biological 
Sciences, University of Karachi, weighing about 180-200 
g. Animals were kept individually in their cages in a quiet 
room for at least a week so that the rats adapt to the 
laboratory environment. Experiment was approved by 
institutional Board of Advance Studies and Research 
(BASR no: 03344/Sc), University of Karachi and 
performed in accordance with National Institute of Health 
Guide for Care and Use of Laboratory Animals 
(Publication No. 85-23, revised 1996). All experimental 
procedures were made in a balance design to avoid the 
effect of time and order. 
 
Drug 
Zolmitriptan was used in the experiment purchased from 
Sigma Aldrich. Drug was prepared in distilled water and 
administered to the test animals at the dose of 0.3 mg/kg 
orally. Untreated rats received an equal volume of 
distilled water. Effects of zolmitriptan were monitored 
after 30 min of treatment as it has been reported to 
produce effects within half an hour when administered 
orally (Bahra et al., 2000). 
 
Experimental protocol 
Animals (n = 24) were randomly divided into two 
experimental groups control (n = 12) and test (n=12). Test 
was subjected to chronic restraint stress in restrainer tube 
following the procedure as reported earlier (Nawaz et al., 
2017). The stress procedure was continued for 19 days for 
4 h daily till the appearance of depressive symptoms in 
rats. Depression was assessed by forced swim test (FST). 
After developing depression-like symptoms in rats, 
pattern separation test for similar new object (PST-SNO) 
and pattern separation for different location of object 
(PST-DLO) were monitored. Morris water maze (MWM) 
test was also conducted to monitor spatial memory. After 
collecting the behavioral data, both groups were further 
divided into two groups. One was treated with saline 
whereas second was administered with zolmitriptan orally 
at the selected dose. After 30 min of administration rats 
were again subjected to behavioral analyses including 
FST, PST-SNO, PST-DLO and MWM. Behaviors were 
performed between 0900-1500 h. All procedures were 
conducted in a balanced design to minimize the effect of 
order and time.   Results of behavioral testing before and 
after the drug treatment were reported at the end of the 
experiment.   
 
Behavioral protocols 
Assessment of depression-like illness 
Expression for depression was monitored by FST 
paradigm. The apparatus and procedure was essentially 
same as described previously (Nawaz et al., 2017). 
 
Pattern separation for similar new object (PST-SNO) 
This test was conducted to evaluate the ability of rats to 
differentiate between similar but new objects. This test 
has been suggested to determine the tendency of pattern 
separation to identify the minute differences between two 
different objects. The apparatus consisted of an open field 
40×40×40 cm. The test comprised of three sessions; 
habituation, familiarization and test sessions. During 
habituation, each rat was placed in the box and allowed to 
explore the area for 10 min in order to habituate with the 
box. After 24 h of habituation, two similar objects were 
placed in the box and rat was allowed to explore both 
objects for 5 min so that rat got familiarized with both 
objects. Test session was carried out after 20 min of 
familiarization phase during which one of the object was 
replaced by a new but similar object. The old object 
which was not replaced was designated as ‘a’ whereas the 
new object was assigned as ‘b’. During test session 
exploring time for each object was recorded. 
Discrimination index (DI) was calculated by using the 
formula (b-a/a+b), where ‘a’ is the time to sniff the old 
object and ‘b’ is the time to sniff the new object placed 
during test session. This test based on the recognizing 
ability of rodent using olfactory cues. The discrimination 
index ranges between -1 to +1. The lower values of DI 
represent inability of rat to differentiate between similar 
but new objects. 
 
Pattern separation test for different location of object 
(PST-DLO) 
This test was also used to analyze the ability of pattern 
separation in rats. This test was based on the ability to 
discriminate similar events from one another (van Hagen 
et al., 2015). In this test an apparatus having the 
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dimension of 76×76×42 was used as an open field area. 
This test also comprised of three sessions; habituation, 
familiarization and test sessions. Rat was allowed to 
habituate with the open field arena during habituation for 
10 min which was followed by familiarization phase after 
24 h. During familiarization two massive and identical 
(12×12×12 cm) wooden blocks were placed in the middle 
area on a same horizontal line. Rat introduced into open 
field area facing towards the wall and was allowed to 
explore both objects for 5 min. After 20 min of second 
phase, test session was conducted during which one of the 
objects was displaced from its position to a definite point 
in order to change its location so that the objects aligned 
diagonally. Time to sniff both objects was recorded during 
testing phase. The object which was not displaced from its 
location was designated as ‘a’ whereas the object with 
new location was named as ‘b’. DI was calculated by the 
same formula as mentioned above. DI value ranges 
between -1 to +1. The impaired pattern separation was 
determined by lower DI values indicating that rat was 
unable to identify the new location of displaced object.  
 
Assessment of spatial memory by Morris water maze 
(MWM) 
The dimensions of the apparatus used for MWM and its 
procedure were same as described earlier (Liaquat et al., 
2018).  
 
STATISTICAL ANALYSIS 
  
One-way ANOVA followed by Tukey’s test for post hoc 
analysis was used for the analysis of data before and after 
the treatment of zolmitriptan. FST, PST-SNO, PST-DLO, 
MWM were included in this analysis. Values of p<0.05 
were considered as a statistically significant difference. 
 
RESULTS 
 
Effects of stress and zolmitriptan on FST 
In present study depression-like behavior was monitored 
by using FST paradigm before and after treatment of 
zolmitriptan. Test was conducted after 19 days of stress 
exposure. It was observed that there were significant 
effects of stress on struggling time [F(3, 20) =20.033] and 
immobility time [F(3, 20) =7.736]. Nineteen days of stress 
exposure significantly induced depression-like symptoms 
in rats. DEP group showed decreased struggling time and 
increased immobility time as compared controls. 
Zolmitriptan treatment was started after observing the 
depressive symptoms. Depression was again analyzed 
after single dose of zolmitriptan and data showed 
significant effects of zolmitriptan treatment on struggling 
time [F(3, 20) =16.963] and immobility time [F(3, 20) 
=7.593]. Depression (DEP) group showed significantly 
decreased struggling time and increased immobility time 
as compared to control group whereas zolmitriptan 
treatment significantly reduced depression-like symptoms 
in depression + zolmitriptan (DEP+Zolmi) group. This 
group performed well in FST paradigm and showed 
significantly increased struggling time and decreased 
immobility time when compared to DEP group.   
 
Effects of stress and zolmitriptan on PST-SNO  
Effect of depression on pattern separation was observed 
by PST-SNO. In this test discrimination between similar 
new objects was analyzed. It was observed that 
depression causes significant impairment in pattern 
separation [F(3, 20) = 78.98]. DEP group showed decreased 
values of DI as compared to controls. After zolmitriptan 
treatment there was significant increase in DI [F(3, 20) 
=51.142]. DEP group were unable to discriminate 
between similar new object as compared to control group. 
Whereas, DEP + Zolmi group significantly distinguished 
between similar new object as compared to DEP group.  
 
Effects of stress and zolmitriptan on PST-DLO  
There was another parameter of pattern separation named 
as PST-DLO in which discrimination between different 
locations of object was monitored. It was observed that 
DEP group were unable to distinguish the change in 
location of object [F(3, 20) =17.506]. DEP groups showed 
decreased values of DI as compared to controls. After 
zolmitriptan treatment there was significant increase in DI 
[F(3, 20) =18.369]. Zolmitriptan treatment ameliorated 
pattern separation impairment as DEP + Zolmi group 
showed improved pattern separation as compare to DEP 
group. 
 
Effects of stress and zolmitriptan on MWM 
MWM test was used for the evaluation of spatial memory. 
It was observed that depression menace the spatial 
memory. MWM showed significant decrease in time spent 
in target quadrant [F(3, 20) =14.525]. DEP group showed 
significantly decreased time spent in target quadrant as 
compare to control group. There was no significant 
difference in latency to reach target quadrant. After 
zolmitriptan treatment time spent [F(3, 20) =8.038] and 
latency to reach target quadrant in target quadrant were 
[F(3, 20) =40.420]. DEP group spent less time in target 
quadrant as compared to control and took more time to 
reach target quadrant as compared to control. Zolmitriptan 
treated rats performed well in MWM as compared to 
control rats, time spent in target quadrant was non-
significant but they reached more quickly in target 
quadrant as compared to controls. DEP+Zolmi group 
spent non-significantly more time as compare to DEP 
group and reached to target quadrant more quickly as 
compared to DEP group. 
 
DISCUSSION 
 
Chronic stress is considered as one of the major causes for 
the onset of depression (Duman, 2014).  In present study 
animals that were exposed to 19 days of chronic restraint 
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Fig. 1: Effects of stress and zolmitriptan on depressive-like symptoms were observed by force swim test in terms of 
(A) struggling time and (B) immobility time. Data is represented as mean±SEM (n=6). Significant difference were 
obtained by Tukey’s post hoc test; *p<0.05, **p<0.01 as compared to control group; ++p<0.01 as compared to DEP 
+ Zolmi group.    
  
Fig. 2: Effects of stress and zolmitriptan on pattern 
separation function assessed for similar new object. 
Data is represented as mean±SEM (n=6). Significant 
difference were obtained by Tukey’s post hoc test; 
**p<0.01 as compared to control group; +p<0.01 as 
compared to DEP + Zolmi group.    
Fig. 3: Effects of stress and zolmitriptan on pattern 
separation function analyzed for different location of 
object. Data is represented as mean±SEM (n=6). 
Significant difference were obtained by Tukey’s post hoc 
test; **p<0.01 as compared to control group; ++p<0.01 as 
compared to DEP + Zolmi group.   
  
Fig. 4: Effects of stress and zolmitriptan on spatial memory function observed by Morris water maze in terms of (A) 
latency to reach and (B) time spent in target quadrant. Data is represented as mean±SEM (n=6). Significant 
difference were obtained by Tukey’s post hoc test; *p<0.05 **p<0.01 as compared to control group; ++p<0.01 as 
compared to DEP + Zolmi group.    
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 stress showed depression-like symptoms evident by 
decreased struggling time and increased immobility time 
observed in FST. Previous studies have reported the 
implication of 5-HT-1B receptor in the pathophysiology 
of depression (Ruf and Bhagwagar, 2009). 5-HT-1B 
agonist CP-94,253 showed biphasic effect on 5-HT 
release. At low doses it induced decrease in 5-HT release 
whereas, administration at high doses resulted in 
increased 5-HT release due desensitization of presynaptic 
receptors (Adell et al., 2001). It has been suggested that 
down regulation of 5-HT-1B autoreceptor mediates 
antidepressant effects. In this regard agonist of 5-HT-1B 
provides a more selective approach for quicker 
desensitization of 5-HT-IB autoreceptors (Tiger et al., 
2018). In this study administration of zolmitriptan after 
the appearance of depressive symptoms in rats 
significantly reduced behavioral despair in FST paradigm. 
This suggests the desensitization of 5-HT-1B autoreceptor 
at the given dose which might have increased the release 
of 5-HT in synapse and produced antidepressant effects.  
 
It has been shown that depression causes reduction in 
density of presynaptic and post synaptic memory related 
proteins in hippocampus, which impairs memory and 
behavioral responses (Jianhua et al., 2016). Studies have 
reported a number of consequences of depression but in 
this study depression-associated memory loss was 
focused. Pseudodementia is a cognitive impairment that 
includes mood disturbances and reduced performance. It 
has been suggested that condition can be reversed unlike 
other psychiatric illness (Tanner at al., 2015). It has been 
observed that depressive pseudodementia patients can 
perform better as compared to patients with Alzheimer’s 
and true dementia so, there must be a criteria to find the 
difference between true dementia and pseudodementia so 
that it can be treated more accurately (Kang et al., 2014). 
It has been reported that the memory loss due to 
depression primarily affects the pattern separation and the 
patient is unable to recognize the difference between two 
similar but different objects (Gandy et al., 2017). In 
rodents, assessment of pattern separation is specifically 
designed to monitor pseudodementia (van Hagen et al., 
2015). In present research it was observed that depressive 
rats were not capable to distinguish among similar new 
objects and change in position of objects. The impaired 
pattern separation ability indicates that some changes 
occurred in brain which may be related to primary storage 
capacity of brain or it may be due to poor concentration. It 
has been described earlier that in depression hippocampal 
neurotransmission decreased leading to impaired memory 
function (Eriksson et al., 2013). In present study a 
condition similar to pseudodementia was observed in rats 
which may be due to the consequence of depression so, it 
can be postulated that depression causes structural and 
functional changes in brain that affect memory function 
and cognition.  
It is observed that depression-like illness is related to the 
reduction in brain 5-HT levels (Lin et al., 2014). 
Previously, it has been shown that activation of 5-HT-1B 
heteroreceptors produced antidepressant effects in animals 
(Nautiyal and Hen 2017). One of the 5-HT-1B agonist 
vortioxetine has shown to be involved in the maturation 
of neurons and enhanced neurogenesis. It also produced 
antidepressant effects by repeated administration 
(Guilloux et al., 2013). Activation of the 5-HT-1B 
receptor in the frontal cortex results in an increase in 
acetylcholine (Consolo et al., 1996). This may explain the 
reason of zolmitriptan-mediated attenuation of 
depression-induced memory loss. The current study 
showed that administration of zolmitriptan 5-HT-1B 
agonist produced antidepressant effects observed in FST 
and reversed the condition of pseudodementia. It is well 
established that increased 5-HT levels reduce depression-
like symptoms and hence have positive effects on learning 
and memory function (Haider et al., 2006). In previous 
research it has been shown that 5-HT-1B receptors are 
widely present in hippocampal circuitries and they 
regulate hippocampal neurotransmission. 5-HT-1B 
receptor ligands therefore can be used for the treatment of 
cognitive impairment in psychiatric disorders and related 
cognitive impairment (Eriksson et al., 2013). However, 
further research is needed to justify the role of 5-HT-1B 
agonists in depression and depression-associated memory 
loss at different doses as previous data related to the role 
of 5-HT-1B receptors is contradictory (Yohn et al., 2017).  
 
CONCLUSION 
 
It is concluded from this study that 5-HT-1B agonists can 
be considered for the treatment of depression.  In future, 
however, studies are required to validate the result of this 
study. The drug, zolmitriptan, used in this study can be 
used for treatment of depression and to cure depression-
associated secondary health issues such as 
pseudodementia.  
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